Neurocrine Biosciences (NBIX) Other Accumulated Expenses (2011 - 2026)
Neurocrine Biosciences (NBIX) posted quarterly Other Accumulated Expenses of $66.2 million for Q2 2026, up 16.55% year-over-year from $56.8 million in Q2 2025, and up 12.78% on a QoQ basis from $58.7 million in Q1 2026.
Neurocrine Biosciences (NBIX) Other Accumulated Expenses (2011 - 2026) Analysis & Trends
Neurocrine Biosciences has reported Other Accumulated Expenses for 16 years, with the latest figure at $66.2 million in Q2 2026.
- Other Accumulated Expenses for Q2 2026 came in at $66.2 million, up 16.55% year-over-year; the trailing twelve-month figure through Jun 2026 was $66.2 million (up 16.55% YoY), and the FY2025 annual result was $69.1 million, up 49.89% from the prior year.
- Other Accumulated Expenses grew to $66.2 million in Q2 2026, from $58.7 million in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $69.1 million in Q4 2025 and troughed at $17.6 million in Q1 2022.
- A 5-year average of $37.9 million and a median of $36.8 million in 2024 frame the typical range for Other Accumulated Expenses.
- The widest annual swing landed in 2022, when Other Accumulated Expenses declined 9.5%; it then soared 99.46% in 2024.
- A 5-year view of Other Accumulated Expenses shows it stood at $20.7 million in 2022, then surged by 73.43% to $35.9 million in 2023, then advanced by 28.41% to $46.1 million in 2024, then jumped by 49.89% to $69.1 million in 2025, then decreased by 4.2% to $66.2 million in 2026.
- Per Business Quant data, the three most recent Other Accumulated Expenses figures were $66.2 million in Q2 2026, $58.7 million in Q1 2026, and $69.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Alkermes | 8.14 Bn | 7.48 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66.20 Mn |
| Mar 31, 2026 | 58.70 Mn |
| Dec 31, 2025 | 69.10 Mn |
| Sep 30, 2025 | 53.70 Mn |
| Jun 30, 2025 | 56.80 Mn |
| Mar 31, 2025 | 47.70 Mn |
| Dec 31, 2024 | 46.10 Mn |
| Sep 30, 2024 | 37.00 Mn |
| Jun 30, 2024 | 40.00 Mn |
| Mar 31, 2024 | 36.70 Mn |
| Dec 31, 2023 | 35.90 Mn |
| Sep 30, 2023 | 18.70 Mn |
| Jun 30, 2023 | 21.20 Mn |
| Mar 31, 2023 | 18.40 Mn |
| Dec 31, 2022 | 20.70 Mn |
| Sep 30, 2022 | 18.10 Mn |
| Jun 30, 2022 | 20.00 Mn |
| Mar 31, 2022 | 17.60 Mn |
| Dec 31, 2021 | 20.00 Mn |
| Sep 30, 2021 | 20.00 Mn |